STAT3 and prostate carcinoma: In fact, Méndez-Clemente et al. [65] noticed that the simultaneous inhibition of STAT-3 and IL-6R via the application of stattic and tocilizumab suppresses prostate cancer cell proliferation, migration, and invasion by disrupting the IL-6/IL-6R/STAT-3 signaling pathway.